Stoke Therapeutics (NASDAQ:STOK) Stock Price Up 6.8%

Stoke Therapeutics, Inc. (NASDAQ:STOKGet Rating)’s share price rose 6.8% on Tuesday . The stock traded as high as $13.71 and last traded at $13.55. Approximately 6,377 shares changed hands during trading, a decline of 98% from the average daily volume of 319,082 shares. The stock had previously closed at $12.69.

STOK has been the topic of several recent analyst reports. Zacks Investment Research downgraded Stoke Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, March 16th. Jefferies Financial Group began coverage on Stoke Therapeutics in a research note on Monday, January 31st. They set a “buy” rating and a $50.00 target price on the stock. Bank of America dropped their price objective on Stoke Therapeutics from $43.00 to $40.00 and set a “buy” rating on the stock in a research note on Wednesday, March 16th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a research note on Friday, April 1st. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Stoke Therapeutics has a consensus rating of “Buy” and a consensus price target of $46.29.

The company has a market capitalization of $535.88 million, a price-to-earnings ratio of -6.09 and a beta of 0.65. The business has a 50-day moving average price of $19.90 and a 200-day moving average price of $21.07.

Stoke Therapeutics (NASDAQ:STOKGet Rating) last issued its quarterly earnings results on Tuesday, May 10th. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of $0.36 by ($1.02). Equities research analysts predict that Stoke Therapeutics, Inc. will post -1.66 EPS for the current fiscal year.

Several hedge funds have recently modified their holdings of the company. Goldman Sachs Group Inc. grew its stake in Stoke Therapeutics by 26.7% in the third quarter. Goldman Sachs Group Inc. now owns 172,749 shares of the company’s stock valued at $4,395,000 after purchasing an additional 36,361 shares in the last quarter. HighVista Strategies LLC purchased a new position in Stoke Therapeutics in the third quarter valued at about $1,211,000. Deutsche Bank AG grew its stake in Stoke Therapeutics by 116.4% in the third quarter. Deutsche Bank AG now owns 27,195 shares of the company’s stock valued at $693,000 after purchasing an additional 14,628 shares in the last quarter. Renaissance Technologies LLC grew its stake in Stoke Therapeutics by 1.8% in the third quarter. Renaissance Technologies LLC now owns 82,800 shares of the company’s stock valued at $2,106,000 after purchasing an additional 1,500 shares in the last quarter. Finally, Russell Investments Group Ltd. purchased a new position in Stoke Therapeutics in the fourth quarter valued at about $319,000. Institutional investors and hedge funds own 99.87% of the company’s stock.

Stoke Therapeutics Company Profile (NASDAQ:STOK)

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression.

See Also

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.